Mathew S Maurer

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/191462/publications.pdf

Version: 2024-02-01

309 papers	22,886 citations	13865 67 h-index	9860 141 g-index
316 all docs	316 docs citations	316 times ranked	19195 citing authors

#	Article	IF	Citations
1	The Wiggers Diagram: Hemodynamic Changes in Cardiac Amyloidosis. Journal of Cardiac Failure, 2023, 29, 217-219.	1.7	2
2	Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS). European Heart Journal, 2022, 43, 391-400.	2.2	105
3	The importance of SPECT cardiac reconstruction for accurate 99mTc-pyrophosphate interpretation in TTR amyloidosis. Journal of Nuclear Cardiology, 2022, 29, 1478-1480.	2.1	2
4	Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness. Heart Failure Reviews, 2022, 27, 785-793.	3.9	31
5	Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€"Evidence Base and Standardized Methods of Imaging. Journal of Cardiac Failure, 2022, 28, e1-e4.	1.7	8
6	Surveillance for disease progression of transthyretin amyloidosis after heart transplantation in the era of novel disease modifying therapies. Journal of Heart and Lung Transplantation, 2022, 41, 199-207.	0.6	9
7	Prescriptions for Potentially Inappropriate Medications from the Beers Criteria Among Older Adults Hospitalized for Heart Failure. Journal of Cardiac Failure, 2022, 28, 906-915.	1.7	7
8	Too Stiff But Still Got Rhythm. JACC: Cardiovascular Imaging, 2022, 15, 30-32.	5.3	4
9	Clinico-histopathologic and single-nuclei RNA-sequencing insights into cardiac injury and microthrombi in critical COVID-19. JCI Insight, 2022, 7, .	5.0	14
10	Amyloid Cardiomyopathy in Older Adults. Current Geriatrics Reports, 2022, 11, 1.	1.1	0
11	Proposed Cardiac End Points for Clinical Trials in Immunoglobulin Light Chain Amyloidosis: Report From the Amyloidosis Forum Cardiac Working Group. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121009038.	3.9	6
12	Critical Comparison of Documents FromÂScientific Societies on CardiacÂAmyloidosis. Journal of the American College of Cardiology, 2022, 79, 1288-1303.	2.8	35
13	Impact of bone marrow minimal residual disease status on quality of organ response in systemic <scp>AL</scp> amyloidosis. American Journal of Hematology, 2022, 97, .	4.1	1
14	Association of Transthyretin Val122Ile Variant With Incident Heart Failure Among Black Individuals. JAMA - Journal of the American Medical Association, 2022, 327, 1368.	7.4	19
15	Remote Cardiac Monitoring in Patients With Heart Failure. JAMA Cardiology, 2022, 7, 556.	6.1	22
16	Racial Differences in Val122Ile-Associated Transthyretin Cardiac Amyloidosis. Journal of Cardiac Failure, 2022, 28, 950-959.	1.7	8
17	Proteomics profiling reveals a distinct high-risk molecular subtype of hypertrophic cardiomyopathy. Heart, 2022, 108, 1807-1814.	2.9	4
18	Impact of light chain isotype on clinical features and outcomes in systemic AL amyloidosis. Leukemia and Lymphoma, 2022, , 1-5.	1.3	0

#	Article	IF	Citations
19	Characteristics of patients with autonomic dysfunction in the Transthyretin Amyloidosis Outcomes Survey (THAOS). Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 175-183.	3.0	7
20	Sex Differences in Wild-Type Transthyretin Amyloidosis: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS). Cardiology and Therapy, 2022, 11, 393-405.	2.6	7
21	Systemic embolism in amyloid transthyretin cardiomyopathy. European Journal of Heart Failure, 2022, 24, 1387-1396.	7.1	23
22	Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update. Orphanet Journal of Rare Diseases, 2022, 17, .	2.7	22
23	Relation of Body Mass Index to Transthyretin Cardiac Amyloidosis Particularly in Black and Hispanic Patients (from the SCAN-MP Study). American Journal of Cardiology, 2022, 177, 116-120.	1.6	2
24	Radiopharmaceutical supply disruptions and the use of 99mTc-hydroxymethylene diphosphonate as an alternative to 99mTc-pyrophosphate for the diagnosis of transthyretin cardiac amyloidosis: An ASNC Information Statement. Journal of Nuclear Cardiology, 2022, 29, 2748-2760.	2.1	4
25	The diagnostic challenges of cardiac amyloidosis: A practical approach to the two main types. Blood Reviews, 2021, 45, 100720.	5.7	15
26	Difference in Metabolomic Response to Exercise between Patients with and without Hypertrophic Cardiomyopathy. Journal of Cardiovascular Translational Research, 2021, 14, 246-255.	2.4	16
27	Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis. European Journal of Heart Failure, 2021, 23, 250-258.	7.1	71
28	Association of Midlife Cardiovascular Risk Factors With the Risk of Heart Failure Subtypes Later in Life. Journal of Cardiac Failure, 2021, 27, 435-444.	1.7	6
29	Predicting the development of adverse cardiac events in patients with hypertrophic cardiomyopathy using machine learning. International Journal of Cardiology, 2021, 327, 117-124.	1.7	12
30	Impact of Tafamidis on Health-Related Quality of Life in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial). American Journal of Cardiology, 2021, 141, 98-105.	1.6	21
31	Diagnosing Transthyretin Cardiac Amyloidosis by Technetium Tc 99m Pyrophosphate. JACC: Cardiovascular Imaging, 2021, 14, 1221-1231.	5.3	52
32	Frailty subtypes and recovery in older survivors of acute respiratory failure: a pilot study. Thorax, 2021, 76, 350-359.	5.6	6
33	Inclusion of Performance Parameters and Patient Context in the Clinical Practice Guidelines for Heart Failure. Journal of Cardiac Failure, 2021, 27, 190-197.	1.7	2
34	Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy. JACC: Heart Failure, 2021, 9, 115-123.	4.1	52
35	Sex Differences in the Phenotype of Transthyretin Cardiac Amyloidosis Due to Val122Ile Mutation: Insights from Noninvasive Pressureâ€“Volume Analysis. Journal of Cardiac Failure, 2021, 27, 67-74.	1.7	20
36	Anticoagulation with warfarin compared to novel oral anticoagulants for atrial fibrillation in adults with transthyretin cardiac amyloidosis: comparison of thromboembolic events and major bleeding. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 30-34.	3.0	31

#	Article	IF	Citations
37	Transthyretin cardiac amyloidosis: A treatable form of heart failure with a preserved ejection fraction. Trends in Cardiovascular Medicine, 2021, 31, 59-66.	4.9	14
38	Editorial for â€œReference Ranges, Diagnostic and Prognostic Utility of Native <scp>T1</scp> Mapping and Extracellular Volume for Cardiac Amyloidosis: A Metaâ€analysisâ€• Journal of Magnetic Resonance Imaging, 2021, 53, 1469-1470.	3.4	1
39	Response by Unlu et al to Letter Regarding Article, â€œPolypharmacy in Older Adults Hospitalized for Heart Failureâ€• Circulation: Heart Failure, 2021, 14, e008305.	3.9	1
40	Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2021, 42, 1554-1568.	2.2	434
41	Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology <scp>W</scp>orking <scp>G</scp>roup on <scp>M</scp>yocardial and <scp>P</scp>ericardial <scp>D</scp>iseases. European Journal of Heart Failure, 2021, 23, 512-526.	7.1	153
42	The association of prior carpal tunnel syndrome surgery with adverse cardiovascular outcomes and long-term mortality after aortic valve replacement. IJC Heart and Vasculature, 2021, 33, 100741.	1.1	0
43	ATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtable. Orphanet Journal of Rare Diseases, 2021, 16, 204.	2.7	11
44	False Positive 99mTc-Pyrophosphate Scanning Leading to Inappropriate Tafamidis Prescriptions. JACC: Cardiovascular Imaging, 2021, 14, 2042-2044.	5.3	13
45	Cognition predicts days-alive-out-of-hospital after LVAD implantation. International Journal of Artificial Organs, 2021, 44, 952-955.	1.4	5
46	Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis. Circulation Research, 2021, 128, 1554-1575.	4.5	52
47	Characteristics of Patients with Late- vs. Early-Onset Val30Met Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey (THAOS). Neurology and Therapy, 2021, 10, 753-766.	3.2	14
48	Prefrailty, impairment in physical function, and risk of incident heart failure among older adults. Journal of the American Geriatrics Society, 2021, 69, 2486-2497.	2.6	14
49	Prediction of Genotype Positivity in Patients With Hypertrophic Cardiomyopathy Using Machine Learning. Circulation Genomic and Precision Medicine, 2021, 14, e003259.	3.6	8
50	Phenotypic Differences of Glu89Gln Genotype in ATTR Amyloidosis From Endemic Loci: Update From THAOS. Cardiology and Therapy, 2021, 10, 481-490.	2.6	8
51	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€”Evidence Base and Standardized Methods of Imaging. Circulation: Cardiovascular Imaging, 2021, 14, e000029.	2.6	48
52	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2â€”Diagnostic Criteria and Appropriate Utilization. Circulation: Cardiovascular Imaging, 2021, 14, e000030.	2.6	16
53	Comprehensive Proteomics Profiling Reveals Circulating Biomarkers of Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2021, 14, e007849.	3.9	26
54	Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2â€”evidence base and standardized methods of imaging. Journal of Nuclear Cardiology, 2021, 28, 1769-1774.	2.1	34

#	Article	IF	Citations
55	Relation between Modified Body Mass Index and Adverse Outcomes after Aortic Valve Implantation. American Journal of Cardiology, 2021, 153, 94-100.	1.6	2
56	Gene Editing â€" A Cure for Transthyretin Amyloidosis?. New England Journal of Medicine, 2021, 385, 558-559.	27.0	8
57	Deep Learning Analysis of Echocardiographic Images to Predict Positive Genotype in Patients With Hypertrophic Cardiomyopathy. Frontiers in Cardiovascular Medicine, 2021, 8, 669860.	2.4	10
58	Factors associated with changes in serum transthyretin after treatment with tafamidis and outcomes in transthyretin cardiac amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, , 1-2.	3.0	4
59	Cardiopulmonary exercise testing in patients with Cardiac Amyloidosis. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 545-548.	0.4	6
60	Two Decades of Cardiac Amyloidosis. JACC: CardioOncology, 2021, 3, 522-533.	4.0	20
61	Recognition and Implications of Undiagnosed Cardiac Amyloid Patients in HFpEF Trials. JACC: Heart Failure, 2021, 9, 803-806.	4.1	3
62	Cardiac Scintigraphy and Screening for Transthyretin Cardiac Amyloidosis. Circulation, 2021, 144, 1005-1007.	1.6	8
63	Effects of Septal Reduction Therapy on Acute Cardiovascular Events and All-Cause Mortality in Patients with Hypertrophic Cardiomyopathy. International Heart Journal, 2021, 62, 1035-1041.	1.0	2
64	Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis. Blood, 2021, 138, 2632-2641.	1.4	48
65	The Potential Role of EHR data in optimizing eligibility criteria definition for cardiovascular outcome trials. International Journal of Medical Informatics, 2021, 156, 104587.	3.3	0
66	Sex-Related Risk of Cardiac Involvement in Hereditary Transthyretin Amyloidosis. JACC: Heart Failure, 2021, 9, 736-746.	4.1	26
67	Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey. JACC: CardioOncology, 2021, 3, 537-546.	4.0	21
68	Cardiovascular Diseases That Have Emerged From the Darkness. Journal of the American Heart Association, 2021, 10, e021095.	3.7	5
69	ATTR Amyloidosis: Current and Emerging Management Strategies. JACC: CardioOncology, 2021, 3, 488-505.	4.0	56
70	Lack of Association Between Neurohormonal Blockade and Survival in Transthyretin Cardiac Amyloidosis. Journal of the American Heart Association, 2021, 10, e022859.	3.7	19
71	Can lightning strike twice? Wild-type transthyretin cardiac amyloidosis associated with rare liver disease. Oxford Medical Case Reports, 2021, 2021, omab113.	0.4	0
72	Impact of Light Chain Isotype on Clinical Features and Outcomes in Systemic AL Amyloidosis. Blood, 2021, 138, 4726-4726.	1.4	0

#	Article	IF	Citations
73	A Proposal to Accelerate Widespread Implementation of Geriatric Cardiology. Trends in Cardiovascular Medicine, 2021, , .	4.9	1
74	158â€ƒRacial differences in val122Ile associated transthyretin cardiac amyloidosis. European Heart Journal Supplements, 2021, 23, .	0.1	0
75	Abstract 9735: Cost Effectiveness of Screening for Valvular Heart Disease Using the Valvenet Deep Learning Electrocardiogram Model. Circulation, 2021, 144, .	1.6	0
76	Estimating cancer risk from 99mTc pyrophosphate imaging for transthyretin cardiac amyloidosis. Journal of Nuclear Cardiology, 2020, 27, 215-224.	2.1	7
77	Cardiac Amyloidosis. , 2020, , 301-310.e3.		1
78	Eosinophils, Lymphocytes, and Myocytes, Oh My: HIV-Associated Myocarditis. American Journal of Medicine, 2020, 133, 52-55.	1.5	1
79	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2â€"Diagnostic criteria and appropriate utilization. Journal of Nuclear Cardiology, 2020, 27, 659-673.	2.1	97
80	99mTechnetium pyrophosphate scintigraphy with cadmium zinc telluride cameras is a highly sensitive and specific imaging modality to diagnose transthyretin cardiac amyloidosis. Journal of Nuclear Cardiology, 2020, 27, 371-380.	2.1	14
81	Prescribing Patterns of HeartÂFailure-Exacerbating Medications Following a Heart Failure Hospitalization. JACC: Heart Failure, 2020, 8, 25-34.	4.1	21
82	Tafamidisâ€"A Pricey Therapy for a Not-So-Rare Condition. JAMA Cardiology, 2020, 5, 247.	6.1	33
83	Stabilization of Cardiac Function With Diflunisal in Transthyretin (ATTR) Cardiac Amyloidosis. Journal of Cardiac Failure, 2020, 26, 753-759.	1.7	57
84	Markers of nutritional status and inflammation in transthyretin cardiac amyloidosis: association with outcomes and the clinical phenotype. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 73-80.	3.0	17
85	The quintessential form of diastolic heart failure in older adults: Wild type transthyretin cardiac amyloidosis. Clinical Cardiology, 2020, 43, 171-178.	1.8	5
86	Comparing outcomes for infiltrative and restrictive cardiomyopathies under the new heart transplant allocation system. Clinical Transplantation, 2020, 34, e14109.	1.6	14
87	Diuretic Dose and NYHA Functional Class Are Independent Predictors of Mortality in Patients With Transthyretin Cardiac Amyloidosis. JACC: CardioOncology, 2020, 2, 414-424.	4.0	37
88	The Amyloidosis Forum: a public private partnership to advance drug development in AL amyloidosis. Orphanet Journal of Rare Diseases, 2020, 15, 268.	2.7	9
89	Response by Kazi et al to Letter Regarding Article, â€œCost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathyâ€• Circulation, 2020, 142, e212-e213.	1.6	1
90	Cardiac Amyloidosis is Underdiagnosed in Patients Undergoing Transcatheter Aortic Valve Replacement. Structural Heart, 2020, 4, 512-514.	0.6	1

#	Article	IF	Citations
91	Polypharmacy in Older Adults Hospitalized for Heart Failure. Circulation: Heart Failure, 2020, 13, e006977.	3.9	102
92	Outcomes after heart transplantation for al compared to ATTR cardiac amyloidosis. Clinical Transplantation, 2020, 34, e14028.	1.6	15
93	Gerotechnology for Older Adults With Cardiovascular Diseases. Journal of the American College of Cardiology, 2020, 76, 2650-2670.	2.8	66
94	Systemic Amyloidosis due to Monoclonal Immunoglobulins. Hematology/Oncology Clinics of North America, 2020, 34, 1055-1068.	2.2	5
95	Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner. BMC Family Practice, 2020, 21, 198.	2.9	60
96	Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2020, 396, 759-769.	13.7	481
97	A Peak into the Pace of CardiacÂAmyloidosis. JACC: Clinical Electrophysiology, 2020, 6, 1155-1157.	3.2	1
98	Transition of a Large Tertiary Heart Failure Program in Response to the COVID-19 Pandemic. Circulation: Heart Failure, 2020, 13, e007516.	3.9	17
99	Early-Onset of Transthyretin Amyloidosis in a Young Afro-Caribbean Woman With Thr60Ala Mutation. JACC: Case Reports, 2020, 2, 2063-2067.	0.6	2
100	Cardiac Scintigraphy With Technetium-99m-Labeled Bone-Seeking Tracers for Suspected Amyloidosis. Journal of the American College of Cardiology, 2020, 75, 2851-2862.	2.8	131
101	Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. Circulation, 2020, 142, e7-e22.	1.6	338
102	DISCOVERY: prevalence of transthyretin (TTR) mutations in a US-centric patient population suspected of having cardiac amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 223-230.	3.0	17
103	Initial Monthly Cost of Tafamidisâ€"the Real Price for Patientsâ€"Reply. JAMA Cardiology, 2020, 5, 848.	6.1	3
104	Norma: Participant 1,001 and the Value of Clinical Research. Journal of the American Geriatrics Society, 2020, 68, 2407-2408.	2.6	0
105	Untangling the physiology of transthyretin cardiac amyloidosis by leveraging echocardiographically derived pressureâ€“volume indices. European Heart Journal, 2020, 41, 1448-1450.	2.2	9
106	Extrapulmonary manifestations of COVID-19. Nature Medicine, 2020, 26, 1017-1032.	30.7	2,300
107	Peripheral neuropathy symptoms in wild type transthyretin amyloidosis. Journal of the Peripheral Nervous System, 2020, 25, 265-272.	3.1	21
108	Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy. Circulation, 2020, 141, 1214-1224.	1.6	147

#	Article	IF	Citations
109	Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR). Cardiovascular Drugs and Therapy, 2020, 34, 357-370.	2.6	55
110	How Should Physicians Assess Myocardial Contraction?. JACC: Cardiovascular Imaging, 2020, 13, 873-878.	5.3	30
111	Impaired systemic venous capacitance: the neglected mechanism in patients with heart failure and a preserved ejection fraction?. European Journal of Heart Failure, 2020, 22, 173-176.	7.1	9
112	Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable. Annual Review of Medicine, 2020, 71, 203-219.	12.2	82
113	Salt Taste Sensitivity and Heart Failure Outcomes Following Heart Failure Hospitalization. American Journal of Cardiology, 2020, 127, 58-63.	1.6	2
114	Cardiac amyloidosis in severe aortic stenosis: we can find it but what should we do?. European Journal of Heart Failure, 2020, 22, 1863-1865.	7.1	2
115	Disparities, Uncertainties, and Societal Cost: Precision Medicine and Transthyretin Amyloidosis. American Journal of Medicine, 2020, 133, 892-894.	1.5	2
116	Older Adults Can Successfully Monitor Symptoms Using an Inclusively Designed Mobile Application. Journal of the American Geriatrics Society, 2020, 68, 1313-1318.	2.6	20
117	Characterization of the <scp>inflammatoryâ€metabolic</scp> phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease. European Journal of Heart Failure, 2020, 22, 1551-1567.	7.1	93
118	Durable Mechanical Circulatory Support in Patients With Amyloid Cardiomyopathy. Circulation: Heart Failure, 2020, 13, e007931.	3.9	15
119	Outcomes By Cardiac Stage in Newly Diagnosed AL Amyloidosis: Results from Andromeda. Blood, 2020, 136, 44-45.	1.4	5
120	Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood, 2020, 136, 71-80.	1.4	146
121	Abstract 15821: Patients With Amyloid Cardiomyopathy Who Receive Durable Mechanical Circulatory Support Are at Increased Risk for Mortality and Early Adverse Events. Circulation, 2020, 142, .	1.6	0
122	Sars-Cov-2 Infection and Systemic Light Chain Amyloidosis: The International Society of Amyloidosis' Survey. Blood, 2020, 136, 11-11.	1.4	0
123	Abstract 15242: Increased Mortality Among African American Patients With Heart Failure Caused by Hereditary Transthyretin Amyloid Cardiomyopathy. Circulation, 2020, 142, .	1.6	0
124	Abstract 14398: African Americans With Transthyretin Cardiac Amyloidosis Have a Lower Prevalence of Atrial Fibrillation but Increased Thromboembolic Events Than Caucasians. Circulation, 2020, 142, .	1.6	1
125	Left Ventricular Assist Device Therapy in Older Adults: Addressing Common Clinical Questions. Journal of the American Geriatrics Society, 2019, 67, 2410-2419.	2.6	13
126	Comparison of Effectiveness of Alcohol Septal Ablation Versus Ventricular Septal Myectomy on Acute Care Use for Cardiovascular Disease in Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2019, 124, 1272-1278.	1.6	1

#	Article	IF	Citations
127	Transthyretin Stabilization by AG10 in Symptomatic Transthyretin AmyloidÂCardiomyopathy. Journal of the American College of Cardiology, 2019, 74, 285-295.	2.8	170
128	The Truth Is Unfolding About Transthyretin Cardiac Amyloidosis. Circulation, 2019, 140, 27-30.	1.6	9
129	Association between reduced myocardial contraction fraction and cardiovascular disease outcomes: The Multi-Ethnic Study of Atherosclerosis. International Journal of Cardiology, 2019, 293, 10-16.	1.7	16
130	Days alive and outside of hospital from diagnosis of transthyretin vs. light chain cardiac amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 4-5.	3.0	1
131	Chronotropic incompetence and autonomic dysfunction as mechanisms of dyspnoea in patients with late stage cardiac amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 134-135.	3.0	3
132	One year follow up analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 115-116.	3.0	24
133	Cost-effectiveness of technetium pyrophosphate scintigraphy versus heart biopsy for the diagnosis of transthyretin amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 71-72.	3.0	3
134	Association of Carpal Tunnel Syndrome With Amyloidosis, HeartÂFailure, and Adverse Cardiovascular Outcomes. Journal of the American College of Cardiology, 2019, 74, 15-23.	2.8	77
135	Application of Proteomics Profiling for Biomarker Discovery in Hypertrophic Cardiomyopathy. Journal of Cardiovascular Translational Research, 2019, 12, 569-579.	2.4	17
136	Beyond the Valve and into the Muscle: A Review of Coexisting Aortic Stenosis and Transthyretin Cardiac Amyloidosis. Structural Heart, 2019, 3, 462-468.	0.6	2
137	Perspectives on Implementing a Multidomain Approach to Caring for Older Adults With Heart Failure. Journal of the American Geriatrics Society, 2019, 67, 2593-2599.	2.6	12
138	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2â€"evidence base and standardized methods of imaging. Journal of Nuclear Cardiology, 2019, 26, 2065-2123.	2.1	230
139	Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. Circulation: Heart Failure, 2019, 12, e006075.	3.9	312
140	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2â€"Diagnostic Criteria and Appropriate Utilization. Journal of Cardiac Failure, 2019, 25, 854-865.	1.7	70
141	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€"Evidence Base and Standardized Methods of Imaging. Journal of Cardiac Failure, 2019, 25, e1-e39.	1.7	107
142	Anticoagulation with Warfarin versus Novel Oral Anticoagulants in Atrial Fibrillation in Amyloid Transthyretin Amyloidosis Cardiomyopathy: A Retrospective Cohort Study. Journal of Cardiac Failure, 2019, 25, S82.	1.7	3
143	Amyloidosis of the Brain and Heart. JACC: Heart Failure, 2019, 7, 129-131.	4.1	5
144	Facilitated Peer Mentorship to Support Aging Research: A REâ€AIM Evaluation of the CoMPAdRE Program. Journal of the American Geriatrics Society, 2019, 67, 804-810.	2.6	8

#	Article	IF	Citations
145	Transthyretin Amyloid Cardiomyopathy. Journal of the American College of Cardiology, 2019, 73, 2872-2891.	2.8	573
146	Trends and causes of hospitalizations in patients with amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 177-178.	3.0	5
147	Cardiac Amyloidosis A Rare Disease in Older Adults Hospitalized for Heart Failure?. Circulation: Heart Failure, 2019, 12, e006169.	3.9	13
148	Deprescribing in Older Adults With Cardiovascular Disease. Journal of the American College of Cardiology, 2019, 73, 2584-2595.	2.8	126
149	Indications for Î²â€Blocker Prescriptions in Heart Failure with Preserved Ejection Fraction. Journal of the American Geriatrics Society, 2019, 67, 1461-1466.	2.6	14
150	Myocardial Contraction Fraction Predicts Cardiovascular Events in Patients With Hypertrophic Cardiomyopathy and Normal Ejection Fraction. Journal of Cardiac Failure, 2019, 25, 450-456.	1.7	19
151	Top Ten Tips Palliative Care Clinicians Should Know About Caring for Patients with Left Ventricular Assist Devices. Journal of Palliative Medicine, 2019, 22, 437-441.	1.1	11
152	Demyelinating Neuropathy in a Patient Treated With Revusiran for Transthyretin (Thr60Ala) Amyloidosis. Journal of Clinical Neuromuscular Disease, 2019, 20, 120-128.	0.7	8
153	Call for New Therapies in HeartÂFailure. JACC: CardioOncology, 2019, 1, 305-306.	4.0	0
154	Clinical Outcomes After Left Ventricular Assist Device Implantation in Older Adults. JACC: Heart Failure, 2019, 7, 1069-1078.	4.1	25
155	Transthyretin Stabilizer Is Associated With Expanding Apical Sparing Area and Improving Global Cardiac Function in a Patient With Wild-Type Cardiac Amyloidosis. Circulation Journal, 2019, 83, 690.	1.6	0
156	Prognosticating in Cardiac Amyloidosis. JACC: Cardiovascular Imaging, 2019, 12, 834-836.	5.3	4
157	Tafamidis for Transthyretin Amyloid Cardiomyopathy. New England Journal of Medicine, 2019, 380, 196-197.	27.0	21
158	Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis. Circulation, 2019, 139, 431-443.	1.6	319
159	Association Between Functional Impairment and Medication Burden in Adults with Heart Failure. Journal of the American Geriatrics Society, 2019, 67, 284-291.	2.6	24
160	TTR (Transthyretin) Stabilizers Are Associated With Improved Survival in Patients With TTR Cardiac Amyloidosis. Circulation: Heart Failure, 2018, 11, e004769.	3.9	78
161	More Than Meets the Eye: Time for a New Imaging Paradigm to Test for Cardiac Amyloidosis. Journal of Cardiac Failure, 2018, 24, 87-89.	1.7	7
162	Myocardial Contraction Fraction. Journal of the American College of Cardiology, 2018, 71, 255-256.	2.8	21

#	Article	IF	Citations
163	Mechanical Circulatory Support Device Utilization and Heart Transplant Waitlist Outcomes in Patients With Restrictive and Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2018, 11, e004665.	3.9	22
164	Standardization of 99mTechnetium pyrophosphate imaging methodology to diagnose TTR cardiac amyloidosis. Journal of Nuclear Cardiology, 2018, 25, 181-190.	2.1	47
165	18Fluorine sodium fluoride positron emission tomography, a potential biomarker of transthyretin cardiac amyloidosis. Journal of Nuclear Cardiology, 2018, 25, 1559-1567.	2.1	46
166	Technetium 99m pyrophosphate radioisotope for diagnosis and prognosis of transthyretin cardiac amyloidosis: A call for collaboration. Journal of Nuclear Cardiology, 2018, 25, 1257-1259.	2.1	2
167	International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM). Circulation, 2018, 137, 1015-1023.	1.6	149
168	The Tafamidis Drug Development Program. JACC Basic To Translational Science, 2018, 3, 871-873.	4.1	5
169	Myocardial Contraction Fraction by M-Mode Echocardiography Is Superior to Ejection Fraction in Predicting Mortality in Transthyretin Amyloidosis. Journal of Cardiac Failure, 2018, 24, 504-511.	1.7	51
170	Home-Delivered Meals Postdischarge From Heart Failure Hospitalization. Circulation: Heart Failure, 2018, 11, e004886.	3.9	81
171	Early Diagnosis of Cardiac Amyloidosis by Carpal Tunnel Surgery. Journal of the American College of Cardiology, 2018, 72, 2051-2053.	2.8	7
172	Metaâ€Analysis Global Group in Chronic (MAGGIC) Heart Failure Risk Score: Validation of a Simple Tool for the Prediction of Morbidity and Mortality in Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association, 2018, 7, e009594.	3.7	87
173	Amyloidosis cardiomyopathy. Current Opinion in Cardiology, 2018, 33, 571-579.	1.8	53
174	Individual and Joint Effects of Pulse Pressure and Blood Pressure Treatment Intensity on Serious Adverse Events in the SPRINT Trial. American Journal of Medicine, 2018, 131, 1220-1227.e1.	1.5	14
175	Multimorbidity in Older Adults With Cardiovascular Disease. Journal of the American College of Cardiology, 2018, 71, 2149-2161.	2.8	216
176	Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis. Circulation: Cardiovascular Imaging, 2018, 11, e006588.	2.6	51
177	Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. New England Journal of Medicine, 2018, 379, 1007-1016.	27.0	1,558
178	Improvement in Global Longitudinal Strain (GLS) Correlates with NT-Probnp Response in Patients with Cardiac Amyloidosis Treated on a Phase 1b Study of Anti-Amyloid Mab Cael-101. Blood, 2018, 132, 958-958.	1.4	12
179	Subcutaneous daratumumab (DARA SC) plus cyclophosphamide, bortezomib, and dexamethasone (CyBorD) in patients (Pts) with newly diagnosed amyloid light chain (AL) amyloidosis: Safety run-in results of andromeda.. Journal of Clinical Oncology, 2018, 36, 8011-8011.	1.6	5
180	Relation of the Myocardial Contraction Fraction, as Calculated from M-Mode Echocardiography, With Incident Heart Failure, Atherosclerotic Cardiovascular Disease and Mortality (Results from the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.6	18

#	Article	IF	Citations
181	Reply. Journal of the American College of Cardiology, 2017, 69, 758-759.	2.8	6
182	The Frailty Phenotype and Palliative Care Needs of Older Survivors of Critical Illness. Journal of the American Geriatrics Society, 2017, 65, 1168-1175.	2.6	31
183	Prognosis Using Planar Imaging in Cardiac Amyloidosisâ€"Reply. JAMA Cardiology, 2017, 2, 704.	6.1	1
184	Salt Taste Recognition in a Heart Failure Cohort. Journal of Cardiac Failure, 2017, 23, 538-544.	1.7	7
185	Recommendations from the Amyloidosis Research Consortium Educational Roundtable at the American College of Cardiology Annual Meeting, 1 April 2016. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 165-166.	3.0	3
186	Interim analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 58-59.	3.0	55
187	Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy) Tj ETQq1 1 0.784314 rgBT /Ove	3.9	59
188	Transthyretin Cardiac Amyloidosis in Older Adults: Optimizing Cardiac Imaging to the Corresponding Diagnostic and Management Goal. Current Cardiovascular Risk Reports, 2017, 11, 1.	2.0	5
189	Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis. Circulation, 2017, 135, 1357-1377.	1.6	319
190	Sexâ€•and Raceâ€Related Differences in Characteristics and Outcomes of Hospitalizations for Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association, 2017, 6, .	3.7	36
191	Can a Left Ventricular Assist Device in Individuals with Advanced Systolic Heart Failure Improve or Reverse Frailty?. Journal of the American Geriatrics Society, 2017, 65, 2383-2390.	2.6	58
192	Hip and knee arthroplasty are common among patients with transthyretin cardiac amyloidosis, occurring years before cardiac amyloid diagnosis: can we identify affected patients earlier?. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 224-228.	3.0	56
193	Peptide probes detect misfolded transthyretin oligomers in plasma of hereditary amyloidosis patients. Science Translational Medicine, 2017, 9, .	12.4	44
194	Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. European Heart Journal, 2017, 38, 2879-2887.	2.2	489
195	Contextualizing Myocardial Infarction: Comorbidities and Priorities in Older Adults. American Journal of Medicine, 2017, 130, 1144-1147.	1.5	9
196	Frailty and Advanced Heart Failure in Older Adults. Current Cardiovascular Risk Reports, 2017, 11, 1.	2.0	3
197	Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis â€“ Report from the Transthyretin Amyloidosis Outcome Survey (THAOS). PLoS ONE, 2017, 12, e0173086.	2.5	50
198	Genotype and Phenotype of Transthyretin Cardiac Amyloidosis. Journal of the American College of Cardiology, 2016, 68, 161-172.	2.8	338

#	Article	IF	Citations
199	Hypertrophic cardiomyopathy: New approaches and a time to reappraise older approaches. Journal of Thoracic and Cardiovascular Surgery, 2016, 152, 983-988.	0.8	7
200	Letter by Cohen and Maurer Regarding Article, â€œPrognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosisâ€. Circulation, 2016, 133, e449.	1.6	0
201	Clinical, ECG and echocardiographic clues to the diagnosis of TTR-related cardiomyopathy. Open Heart, 2016, 3, e000289.	2.3	62
202	Transthyretin Cardiac Amyloidosis in Black Americans. Circulation: Heart Failure, 2016, 9, e002558.	3.9	54
203	Knowledge Gaps in Cardiovascular Care of the Older Adult Population. Circulation, 2016, 133, 2103-2122.	1.6	139
204	Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation, 2016, 133, 2404-2412.	1.6	1,335
205	Serial scanning with technetium pyrophosphate (99mTc-PYP) in advanced ATTR cardiac amyloidosis. Journal of Nuclear Cardiology, 2016, 23, 1355-1363.	2.1	83
206	Multimorbidity is strongly associated with long-term but not short-term mortality after cardiac valve replacement. International Journal of Cardiology, 2016, 215, 417-421.	1.7	3
207	Rationale and design of the Transcatheter Aortic Valve Replacement to UNload the Left ventricle in patients with ADvanced heart failure (TAVR UNLOAD) trial. American Heart Journal, 2016, 182, 80-88.	2.7	142
208	Knowledge Gaps in Cardiovascular Care of Older Adults: A Scientific Statement from the American Heart Association, American College of Cardiology, and American Geriatrics Society: Executive Summary. Journal of the American Geriatrics Society, 2016, 64, 2185-2192.	2.6	56
209	Palliative Care Throughout the Journey of Life With a Left Ventricular Assist Device. Circulation: Heart Failure, 2016, 9, .	3.9	9
210	Gerontechnologies for Older Patients with Heart Failure: What is the Role of Smartphones, Tablets, and Remote Monitoring Devices in Improving Symptom Monitoring and Self-Care Management?. Current Cardiovascular Risk Reports, 2016, 10, 1.	2.0	30
211	Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging. JAMA Cardiology, 2016, 1, 880.	6.1	304
212	Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure. Circulation: Heart Failure, 2016, 9, .	3.9	51
213	Transthyretin Cardiac Amyloidosis in Older Americans. Journal of Cardiac Failure, 2016, 22, 996-1003.	1.7	53
214	Wild-Type Transthyretin Cardiac Amyloidosis: Novel Insights From Advanced Imaging. Canadian Journal of Cardiology, 2016, 32, 1166.e1-1166.e10.	1.7	26
215	Top 10 List for the Cardiovascular Care of Older Adults. American Journal of Medicine, 2016, 129, 901-902.	1.5	1
216	Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis. Neurology and Therapy, 2016, 5, 1-25.	3.2	124

#	Article	IF	Citations
217	Heart failure in older adults: embracing complexity. Journal of Geriatric Cardiology, 2016, 13, 8-14.	0.2	14
218	Improved Cardiovascular Disease Outcomes in Older Adults. F1000Research, 2016, 5, 112.	1.6	21
219	Review and Analysis of Existing Mobile Phone Apps to Support Heart Failure Symptom Monitoring and Self-Care Management Using the Mobile Application Rating Scale (MARS). JMIR MHealth and UHealth, 2016, 4, e74.	3.7	212
220	Syncope in older adults. Journal of Geriatric Cardiology, 2016, 13, 380-6.	0.2	10
221	Relationship Between Accelerometer-Measured Activity and Self-Reported or Performance-Based Function in Older Adults with Severe Aortic Stenosis. Current Geriatrics Reports, 2015, 4, 377-384.	1.1	10
222	A Decision-Making Framework for Objective Risk Assessment in Older Adults with Severe Symptomatic Aortic Stenosis. Current Geriatrics Reports, 2015, 4, 338-346.	1.1	2
223	Identifying Predictors of Taxane-Induced Peripheral Neuropathy Using Mass Spectrometry-Based Proteomics Technology. PLoS ONE, 2015, 10, e0145816.	2.5	28
224	Rationale and Design of the Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy Study (LAPTOP-HF). Journal of Cardiac Failure, 2015, 21, 479-488.	1.7	69
225	Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-type transthyretin amyloidosis (cardiomyopathy). Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2015, 22, 175-180.	3.0	34
226	Evaluating the safety and efficacy of sodium-restricted/Dietary Approaches to Stop Hypertension diet after acute decompensated heart failure hospitalization: Design and rationale for the Geriatric OUt of hospital Randomized MEal Trial in Heart Failure (GOURMET-HF). American Heart Journal, 2015, 169, 342-348.e4.	2.7	15
227	The myocardial contraction fraction is superior to ejection fraction in predicting survival in patients with AL cardiac amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2015, 22, 61-66.	3.0	69
228	Noninvasive Identification of ATTRwt Cardiac Amyloid: The Re-emergence of Nuclear Cardiology. American Journal of Medicine, 2015, 128, 1275-1280.	1.5	58
229	Left Atrial Decompression Pump forÂSevere Heart Failure With PreservedÂEjection Fraction. JACC: Heart Failure, 2015, 3, 275-282.	4.1	67
230	Cardiac amyloidosis: the great pretender. Heart Failure Reviews, 2015, 20, 117-124.	3.9	147
231	Tafamidis in Transthyretin Amyloid Cardiomyopathy. Circulation: Heart Failure, 2015, 8, 519-526.	3.9	110
232	Unveiling wild-type transthyretin cardiac amyloidosis as a significant and potentially modifiable cause of heart failure with preserved ejection fraction. European Heart Journal, 2015, 36, 2595-2597.	2.2	33
233	Paradoxical Low Flow/Low Gradient Severe Aortic Stenosis: an Emerging Phenotype in Older Adults with Valve Disease. Current Geriatrics Reports, 2015, 4, 353-361.	1.1	0
234	What to Expect From the Evolving Field ofÂGeriatric Cardiology. Journal of the American College of Cardiology, 2015, 66, 1286-1299.	2.8	102

#	Article	IF	Citations
235	Use of Implantable Cardioverter-Defibrillators Among Medicare Patients. JAMA - Journal of the American Medical Association, 2015, 314, 1873.	7.4	0
236	Multiple Chronic Conditions and Heart Failure. JACC: Heart Failure, 2015, 3, 551-553.	4.1	11
237	Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. Heart Failure Reviews, 2015, 20, 163-178.	3.9	178
238	In Patients with Light-Chain (AL) Amyloidosis Myocardial Contraction Fraction (MCF) Is a Simple, but Powerful Prognostic Measure That Can be Calculated from a Standard Echocardiogram (ECHO). Blood, 2015, 126, 1774-1774.	1.4	6
239	Results of Phase I Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients with AL Amyloidosis. Blood, 2015, 126, 188-188.	1.4	18
240	Cardiac dysfunction in Î²-carotene-15,15â€²-dioxygenase-deficient mice is associated with altered retinoid and lipid metabolism. American Journal of Physiology - Heart and Circulatory Physiology, 2014, 307, H1675-H1684.	3.2	27
241	Reduced Handgrip Strength as a Marker of Frailty Predicts Clinical Outcomes in Patients With Heart Failure Undergoing Ventricular Assist Device Placement. Journal of Cardiac Failure, 2014, 20, 310-315.	1.7	155
242	The feasibility of measuring frailty to predict disability and mortality in older medical intensive care unit survivors. Journal of Critical Care, 2014, 29, 401-408.	2.2	73
243	Effects of an Interatrial Shunt on Rest and Exercise Hemodynamics: Results of a Computer Simulation in Heart Failure. Journal of Cardiac Failure, 2014, 20, 212-221.	1.7	111
244	Couples Living With Cardiovascular Disease: Effects on the Marital Relationship. Journal of Family Social Work, 2014, 17, 21-36.	0.2	5
245	HFpEF. Journal of the American College of Cardiology, 2014, 64, 550-552.	2.8	12
246	Prevalence and Prognostic Significance of Low QRS Voltage Among the Three Main Types of Cardiac Amyloidosis. American Journal of Cardiology, 2014, 114, 1089-1093.	1.6	154
247	Nuclear imaging modalities for cardiac amyloidosis. Journal of Nuclear Cardiology, 2014, 21, 175-184.	2.1	93
248	Joint Commission Requirements for Discharge Instructions in Patients With Heart Failure: Is Understanding Important for Preventing Readmissions?. Journal of Cardiac Failure, 2014, 20, 641-649.	1.7	61
249	Frailty Assessment in the Cardiovascular Care of Older Adults. Journal of the American College of Cardiology, 2014, 63, 747-762.	2.8	850
250	Dietary Interventions for Heart Failure in Older Adults: Re-Emergence of the Hedonic Shift. Progress in Cardiovascular Diseases, 2014, 57, 160-167.	3.1	14
251	Cardiovascular effects of hemoglobin response in patients receiving epoetin alfa and oral iron in heart failure with a preserved ejection fraction. Journal of Geriatric Cardiology, 2014, 11, 100-5.	0.2	7
252	Treating Anemia in Older Adults With Heart Failure With a Preserved Ejection Fraction With Epoetin Alfa. Circulation: Heart Failure, 2013, 6, 254-263.	3.9	47

#	Article	IF	Citations
253	The Transthyretin Amyloidosis Outcomes Survey (THAOS) registry: design and methodology. Current Medical Research and Opinion, 2013, 29, 77-84.	1.9	50
254	Relation Between Six-Minute Walk Test Performance and Outcomes After Transcatheter Aortic Valve Implantation (from the PARTNER Trial). American Journal of Cardiology, 2013, 112, 700-706.	1.6	70
255	Comparison of cardiac amyloidosis due to wild-type and V122I transthyretin in older adults referred to an academic medical center. Aging Health, 2013, 9, 229-235.	0.3	57
256	^{99m} Tc-Pyrophosphate Scintigraphy for Differentiating Light-Chain Cardiac Amyloidosis From the Transthyretin-Related Familial and Senile Cardiac Amyloidoses. Circulation: Cardiovascular Imaging, 2013, 6, 195-201.	2.6	499
257	THAOS â€“ The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Current Medical Research and Opinion, 2013, 29, 63-76.	1.9	246
258	Secondary Prevention of Atherosclerotic Cardiovascular Disease in Older Adults. Circulation, 2013, 128, 2422-2446.	1.6	166
259	A Prognostic Model for 6-Month Mortality in Elderly Survivors of Critical Illness. Chest, 2013, 143, 910-919.	0.8	56
260	Technetium pyrophosphate myocardial uptake and peripheral neuropathy in a rare variant of familial transthyretin (TTR) amyloidosis (Ser23Asn): a case report and literature review. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2012, 19, 41-46.	3.0	15
261	Cardiac Transplantation in Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2012, 110, 568-574.	1.6	56
262	Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: The Transthyretin Amyloidosis Cardiac Study (TRACS). American Heart Journal, 2012, 164, 222-228.e1.	2.7	209
263	The Impact of Frailty Status on Survival After Transcatheter Aortic Valve Replacement in Older Adults With Severe Aortic Stenosis. JACC: Cardiovascular Interventions, 2012, 5, 974-981.	2.9	411
264	Prevalence and Characteristics of Anergia (Lack of Energy) in Patients With Acute Coronary Syndrome. American Journal of Cardiology, 2012, 110, 1213-1218.	1.6	5
265	Gait Speed and Dependence in Activities of Daily Living in Older Adults With Severe Aortic Stenosis. Clinical Cardiology, 2012, 35, 307-314.	1.8	60
266	Usefulness of Two-Dimensional Echocardiographic Parameters of the Left Side of the Heart to Predict Right Ventricular Failure After Left Ventricular Assist Device Implantation. American Journal of Cardiology, 2012, 109, 246-251.	1.6	96
267	Transthyretin Cardiac Amyloidoses in Older North Americans. Journal of the American Geriatrics Society, 2012, 60, 765-774.	2.6	64
268	Diflunisal for ATTR Cardiac Amyloidosis. Congestive Heart Failure, 2012, 18, 315-319.	2.0	124
269	Cardiac Care for Older Adults. Journal of the American College of Cardiology, 2011, 57, 1801-1810.	2.8	187
270	Heart Failure with Preserved Ejection Fraction: Persistent Diagnosis, Therapeutic Enigma. Current Cardiovascular Risk Reports, 2011, 5, 440-449.	2.0	89

#	Article	IF	Citations
271	Pressure-Volume Relationships in Patients With Transthyretin (ATTR) Cardiac Amyloidosis Secondary to V122I Mutations and Wild-Type Transthyretin. Circulation: Heart Failure, 2011, 4, 121-128.	3.9	84
272	Circulating Activated and Effector Memory T Cells Are Associated with Calcification and Clonal Expansions in Bicuspid and Tricuspid Valves of Calcific Aortic Stenosis. Journal of Immunology, 2011, 187, 1006-1014.	0.8	48
273	Perioperative Outcome and Longâ€Term Mortality for Heart Failure Patients Undergoing Intermediateâ€• and Highâ€Risk Noncardiac Surgery: Impact of Left Ventricular Ejection Fraction. Congestive Heart Failure, 2010, 16, 45-49.	2.0	95
274	Mechanisms Underlying Improvements in Ejection Fraction With Carvedilol in Heart Failure. Circulation: Heart Failure, 2009, 2, 189-196.	3.9	63
275	Comparison of Ventricular Structure and Function in Chinese Patients With Heart Failure and Ejection Fractions >55% Versus 40% to 55% Versus <40%. American Journal of Cardiology, 2009, 103, 845-851.	1.6	67
276	The Prevalence and Impact of Anergia (Lack of Energy) in Subjects With Heart Failure and its Associations With Actigraphy. Journal of Cardiac Failure, 2009, 15, 145-151.	1.7	30
277	Comparison of Blood Volume Characteristics in Anemic Patients With Low Versus Preserved Left Ventricular Ejection Fractions. American Journal of Cardiology, 2008, 102, 1069-1072.	1.6	66
278	Self-Reported Lack of Energy (Anergia) Among Elders in a Multiethnic Community. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2008, 63, 707-714.	3.6	50
279	Left ventricular mass predicts heart failure not related to previous myocardial infarction: the Cardiovascular Health Study. European Heart Journal, 2008, 29, 741-747.	2.2	203
280	Society of Geriatric Cardiology. The American Journal of Geriatric Cardiology, 2007, 16, 205-208.	0.6	0
281	Society of Geriatric Cardiology. The American Journal of Geriatric Cardiology, 2007, 16, 54-55.	0.6	0
282	The Lymphocytic Infiltration in Calcific Aortic Stenosis Predominantly Consists of Clonally Expanded T Cells. Journal of Immunology, 2007, 178, 5329-5339.	0.8	37
283	Cardiac Transplantation Using Extended-Donor Criteria Organs for Systemic Amyloidosis Complicated by Heart Failure. Transplantation, 2007, 83, 539-545.	1.0	73
284	Ventricular Structure and Function in Hypertensive Participants With Heart Failure and a Normal Ejection Fraction. Journal of the American College of Cardiology, 2007, 49, 972-981.	2.8	166
285	Predictors of Survival in De Novo Cardiac Amyloidosis.. Blood, 2007, 110, 2870-2870.	1.4	1
286	The Columbia Cooperative Aging Program: An Interdisciplinary and Interdepartmental Approach to Geriatric Education for Medical Interns. Journal of the American Geriatrics Society, 2006, 54, 520-526.	2.6	33
287	Ventricular Pump Function in Heart Failure with Normal Ejection Fraction: Insights from Pressure-Volume Measurements. Progress in Cardiovascular Diseases, 2006, 49, 182-195.	3.1	28
288	Single-beat estimation of end-diastolic pressure-volume relationship: a novel method with potential for noninvasive application. American Journal of Physiology - Heart and Circulatory Physiology, 2006, 291, H403-H412.	3.2	223

#	Article	IF	Citations
289	Development of Heart Failure in Chronic Hypertensive Dahl Rats. Hypertension, 2006, 47, 901-911.	2.7	125
290	Society of Geriatric Cardiology. The American Journal of Geriatric Cardiology, 2006, 15, 319-321.	0.6	0
291	Society of Geriatric Cardiology. The American Journal of Geriatric Cardiology, 2006, 15, 398-398.	0.6	0
292	Society of Geriatric Cardiology. The American Journal of Geriatric Cardiology, 2006, 15, 263-267.	0.6	0
293	Society of geriatric cardiology. The American Journal of Geriatric Cardiology, 2006, 15, 194-196.	0.6	0
294	Arterial Stiffness in Mild Primary Hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 3326-3330.	3.6	132
295	Ventricular Volume and Length in Hypertensive Diastolic Heart Failure. Journal of the American Society of Echocardiography, 2005, 18, 1051-1057.	2.8	22
296	Left Heart Failure With a Normal Ejection Fraction: Identification of Different Pathophysiologic Mechanisms. Journal of Cardiac Failure, 2005, 11, 177-187.	1.7	184
297	Mechanisms of heart failure with well preserved ejection fraction in dogs following limited coronary microembolization. Cardiovascular Research, 2004, 64, 72-83.	3.8	50
298	Diastolic dysfunction. Journal of the American College of Cardiology, 2004, 44, 1543-1549.	2.8	185
299	The Degree and Timing of Orthostatic Blood Pressure Changes in Relation to Falls in Nursing Home Residents. Journal of the American Medical Directors Association, 2004, 5, 233-238.	2.5	16
300	Dissociation between exercise hemodynamics and exercise capacity in patients with chronic heart failure and marked increase in ejection fraction after treatment with beta-adrenergic receptor antagonists. American Journal of Cardiology, 2003, 91, 356-360.	1.6	11
301	Heart Failure With a Normal Ejection Fraction. Circulation, 2003, 107, 656-658.	1.6	226
302	Myocardial contraction fraction: a volumetric index of myocardial shortening by freehand three-dimensional echocardiography. Journal of the American College of Cardiology, 2002, 40, 325-329.	2.8	73
303	Noncompressibility of myocardium during systole with freehand three-dimensional echocardiography. Journal of the American Society of Echocardiography, 2002, 15, 1503-1506.	2.8	26
304	Atrial fibrillation and falls in the elderly. Clinics in Geriatric Medicine, 2002, 18, 323-337.	2.6	11
305	The Effect of Body Mass Index on Complications from Cardiac Surgery in the Oldest Old. Journal of the American Geriatrics Society, 2002, 50, 988-994.	2.6	36
306	Upright Posture and Postprandial Hypotension in Elderly Persons. Annals of Internal Medicine, 2000, 133, 533.	3.9	55

#	Article	IF	Citations
307	Effects of age on outcome of tilt-table testing. American Journal of Cardiology, 1999, 83, 1055-1058.	1.6	48
308	Should Orthostatic Changes in Blood Pressure be Measured After One or Three Minutes in Elderly Subjects?. The American Journal of Geriatric Cardiology, 1998, 7, 29-33.	0.6	1
309	Prevalence and prognostic significance of exercise-induced supraventricular tachycardia in apparently healthy volunteers. American Journal of Cardiology, 1995, 75, 788-792.	1.6	58